Labiana Health (XMAD:LAB) Ending Cash Position: €5.92 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XMAD:LAB Labiana Health SA XMAD:LAB
57 GF Score
Price €6.65
GF Value €3.59
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Labiana Health Ending Cash Position?

Labiana Health XMAD:LAB -0.75% 57 Ending Cash Position is €5.92 Mil as of Dec. 2025. GuruFocus rates XMAD:LAB with a GF Score™ of 57/100 and a GF Value™ of €3.59 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Labiana Health's Ending Cash Position for the quarter that ended in Dec. 2025 was €5.92 Mil.

Labiana Health's quarterly Ending Cash Position declined from Dec. 2024 (€6.74 Mil) to Jun. 2025 (€3.77 Mil) but then increased from Jun. 2025 (€3.77 Mil) to Dec. 2025 (€5.92 Mil).

Labiana Health's annual Ending Cash Position increased from Dec. 2023 (€2.96 Mil) to Dec. 2024 (€6.74 Mil) but then declined from Dec. 2024 (€6.74 Mil) to Dec. 2025 (€5.92 Mil).

Labiana Health Ending Cash Position Related Terms

Labiana Health Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Labiana Health's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Labiana Health Ending Cash Position Chart

Labiana Health Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 3.28 2.52 2.96 6.74 5.92

Labiana Health Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.96 3.91 6.74 3.77 5.92
XMAD:LAB
57GF Score
Labiana Health SA XMAD:LAB
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Labiana Health Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Labiana Health's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=6.739+-0.824
=5.92

Labiana Health's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=3.77+2.145
=5.92

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €5.92 Mil mean?
Labiana Health (XMAD:LAB) has a Ending Cash Position of €5.92 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Labiana Health and its competitors.
Is Labiana Health's Ending Cash Position too high?
Labiana Health's current Ending Cash Position is €5.92 Mil. Overall, Labiana Health has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Labiana Health's Ending Cash Position compare to ZTS and UTHR?
Labiana Health's Ending Cash Position of €5.92 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Labiana Health and its competitors. Labiana Health's current Ending Cash Position is €5.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labiana Health stock overvalued right now?
Based on GuruFocus' analysis, Labiana Health (XMAD:LAB) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.59, compared to a current price of €6.65 — trading 85.2% above its estimated fair value. The current Ending Cash Position is €5.92 Mil. Labiana Health's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Labiana Health (XMAD:LAB), the current Ending Cash Position is €5.92 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Labiana Health (XMAD:LAB) Overvalued in 2026?

Based on GuruFocus' analysis, Labiana Health stock appears to be overvalued. The current stock price of €6.65 is trading 85.2% above its estimated GF Value™ of €3.59. GuruFocus considers Labiana Health to be Significantly Overvalued.

Key valuation signals for XMAD:LAB:

  • Ending Cash Position: €5.92 Mil
  • GF Value™: €3.59 vs. price of €6.65 (85.2% above fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the XMAD:LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Labiana Health Business Description

Other Exchanges 8RK:Germany
Address Avenida Europa, 34 1st D, Pozuelo de Alarcon, Madrid, ESP, 28023
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include a GMP manufacturer for EU animal and human health industries, a manufacturer specializing in sterile and lyophilized dosage forms, and a source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol. The company operates in two segment Animal Health and Human Health.
57GF Score

Get the complete analysis for XMAD:LAB

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.65
Price
€3.59
GF Value